BioCryst Highlights Pediatric HAE Burden with Real-World Data at ISPOR 2026
Event summary
- BioCryst will present two posters at ISPOR 2026 (May 17–20) on pediatric hereditary angioedema (HAE) burden.
- Study 1: Pediatric HAE patients (2–12 years) had 3x more outpatient visits and higher hospitalization rates than controls.
- Study 2: Caregivers spent >20 hours/week managing HAE, with quality-of-life impacts worsening during attack frequency spikes.
- Data drawn from Komodo claims (2016–2024) and mixed-methods caregiver interviews.
The big picture
BioCryst’s ISPOR presentations underscore the persistent gaps in managing pediatric HAE, where ORLADEYO is the sole approved oral therapy. The focus on caregiver burden aligns with payer sensitivities around holistic disease management, potentially strengthening BioCryst’s value proposition. The data may also inform broader rare disease strategies as competitors like Takeda and Shire (now part of Takeda) refine their HAE portfolios.
What we're watching
- Therapeutic Differentiation
- How BioCryst leverages this data to position ORLADEYO against competitors in pediatric HAE.
- Regulatory Strategy
- Whether real-world evidence accelerates label expansions or supports pricing justifications.
- Pipeline Prioritization
- The pace at which BioCryst advances other rare disease programs given HAE’s sustained unmet needs.
Related topics